These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 10385497)

  • 1. Aggressive cholesterol lowering delays saphenous vein graft atherosclerosis in women, the elderly, and patients with associated risk factors. NHLBI post coronary artery bypass graft clinical trial. Post CABG Trial Investigators.
    Campeau L; Hunninghake DB; Knatterud GL; White CW; Domanski M; Forman SA; Forrester JS; Geller NL; Gobel FL; Herd JA; Hoogwerf BJ; Rosenberg Y
    Circulation; 1999 Jun; 99(25):3241-7. PubMed ID: 10385497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of aggressive and moderate lowering of LDL-cholesterol and low dose anticoagulation on plasma lipids, apolipoproteins and lipoprotein families in post coronary artery bypass graft trial.
    Alaupovic P; Fesmire JD; Hunnighake D; Domanski M; Forman S; Knatterud GL; Forrester J; Herd JA; Hoogwerf B; Campeau L; Gobel FL
    Atherosclerosis; 1999 Oct; 146(2):369-79. PubMed ID: 10532693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pleiotropic effect of lovastatin, with and without cholestyramine, in the post coronary artery bypass graft (Post CABG) trial.
    Domanski M; Tian X; Fleg J; Coady S; Gosen C; Kirby R; Sachdev V; Knatterud G; Braunwald E
    Am J Cardiol; 2008 Oct; 102(8):1023-7. PubMed ID: 18929703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts.
    Post Coronary Artery Bypass Graft Trial Investigators
    N Engl J Med; 1997 Jan; 336(3):153-62. PubMed ID: 8992351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic factors for atherosclerosis progression in saphenous vein grafts: the postcoronary artery bypass graft (Post-CABG) trial. Post-CABG Trial Investigators.
    Domanski MJ; Borkowf CB; Campeau L; Knatterud GL; White C; Hoogwerf B; Rosenberg Y; Geller NL
    J Am Coll Cardiol; 2000 Nov; 36(6):1877-83. PubMed ID: 11092659
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy.
    Hunninghake DB
    Am J Med; 1998 Feb; 104(2A):9S-13S. PubMed ID: 9550501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of an aggressive lipid-lowering strategy on progression of atherosclerosis in the left main coronary artery from patients in the post coronary artery bypass graft trial.
    White CW; Gobel FL; Campeau L; Knatterud GL; Forman SA; Forrester JS; Geller NL; Herd JA; Hickey A; Hoogwerf BJ; Hunninghake DB; Rosenberg Y; Terrin ML;
    Circulation; 2001 Nov; 104(22):2660-5. PubMed ID: 11723015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Benefit of aggressive lipid-lowering therapy: insights from the post coronary artery bypass graft study and other trials.
    White CW
    Am J Med; 1998 Jul; 105(1A):63S-68S. PubMed ID: 9707270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of cholesterol lowering and cardiovascular risk factors on the progression of aortoiliac arteriosclerosis: a quantitative cineangiography study.
    Campeau L; Lespérance J; Bilodeau L; Fortier A; Guertin MC; Knatterud GL
    Angiology; 2005; 56(2):191-9. PubMed ID: 15793608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is aggressive cholesterol control justified? Review of the post-coronary artery bypass graft trial.
    Hunninghake DB
    Am J Cardiol; 1998 Nov; 82(10B):45T-48T. PubMed ID: 9860374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of aorto-saphenous vein bypass narrowing late after coronary artery bypass grafting.
    Rodés-Cabau J; Facta A; Larose E; DeLarochellière R; Déry JP; Nguyen CM; Roy L; Proulx G; Gleeton O; Barbeau G; Noël B; Rouleau J; Boudreault JR; Bertrand OF
    Am J Cardiol; 2007 Aug; 100(4):640-5. PubMed ID: 17697821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of aggressive cholesterol lowering and low-dose anticoagulation on clinical and angiographic outcomes in patients with diabetes: the Post Coronary Artery Bypass Graft Trial.
    Hoogwerf BJ; Waness A; Cressman M; Canner J; Campeau L; Domanski M; Geller N; Herd A; Hickey A; Hunninghake DB; Knatterud GL; White C
    Diabetes; 1999 Jun; 48(6):1289-94. PubMed ID: 10342818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term effects on clinical outcomes of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation in the post coronary artery bypass graft trial. Post CABG Investigators.
    Knatterud GL; Rosenberg Y; Campeau L; Geller NL; Hunninghake DB; Forman SA; Forrester JS; Gobel FL; Herd JA; Hickey A; Hoogwerf BJ; Terrin ML; White C
    Circulation; 2000 Jul; 102(2):157-65. PubMed ID: 10889125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of aggressive lipid controlling therapy for preventing saphenous vein graft disease.
    Hata M; Takayama T; Sezai A; Yoshitake I; Hirayama A; Minami K
    Ann Thorac Surg; 2009 Nov; 88(5):1440-4. PubMed ID: 19853088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of aggressive statin therapy on patients with coronary saphenous vein bypass grafts: a systematic review and meta-analysis of randomized, controlled trials.
    Kang S; Liu Y; Liu XB
    Clin Ther; 2013 Aug; 35(8):1125-36. PubMed ID: 23932462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlates and consequences of diffuse atherosclerosis in men with coronary heart disease. Veterans Affairs High-Density Lipoprotein Intervention Trial Study Group.
    Wilt TJ; Rubins HB; Collins D; O'Connor TZ; Rutan GH; Robins SJ
    Arch Intern Med; 1996 Jun; 156(11):1181-8. PubMed ID: 8639012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality of life after coronary artery bypass graft: results from the POST CABG Trial.
    Fox NL; Hoogwerf BJ; Czajkowski S; Lindquist R; Dupuis G; Herd JA; Campeau L; Hickey A; Barton FB; Terrin ML;
    Chest; 2004 Aug; 126(2):487-95. PubMed ID: 15302735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Elevated levels of plasma homocysteine related to saphenous vein graft disease after coronary artery bypass graft surgery].
    Iwama Y; Mokuno H; Yokoi H; Daida H; Yamaguchi H; Hosoda Y
    J Cardiol; 1998 Dec; 32(6):357-62. PubMed ID: 9914952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statin therapy and saphenous vein graft disease after coronary bypass surgery: analysis from the CASCADE randomized trial.
    Kulik A; Voisine P; Mathieu P; Masters RG; Mesana TG; Le May MR; Ruel M
    Ann Thorac Surg; 2011 Oct; 92(4):1284-90; discussion 1290-1. PubMed ID: 21958773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-density lipoprotein cholesterol and triglycerides as therapeutic targets for preventing and treating coronary artery disease.
    Gotto AM
    Am Heart J; 2002 Dec; 144(6 Suppl):S33-42. PubMed ID: 12486414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.